>May 5, 2011
>November 2, 2010
>November 2, 2010
Escape Therapeutics, Inc. is an early stage biotechnology company focused on accelerating the commercial availability of allogeneic stem cell therapies by solving the key translational hurdle preventing their clinical utility - immune mismatch and subsequent donor rejection.
Invented by Escape's founder Dr. Hantash while at Stanford University, our platform technology represents a significant potential breakthrough that can revolutionize the treatment of numerous medical diseases that require cell and/or organ replacement such as type I diabetes, Parkinson's, and leukemia, amongst others. Escape's innovative technology allows for the creation of the world's first allogeneic, "off-the-shelf" therapy capable of being used in any patient irrespective of their HLA profile without the need for adjunctive immunosuppression, HLA matching, or autologous sourcing.
About Escape Therapeutics
Since its founding in 2006, Escape Therapeutics has dedicated itself to transforming healthcare through discovery, development, and commercialization of innovative stem cell-based curative therapeutics capable of relieving the suffering of children and adults inflicted with devastating diseases or injuries that are currently inadequately treated and/or incurable.
Headquartered in Silicon Valley, California, the company has built an elite team of Stanford-trained scientists with core expertise in stem cell immunology and genetic engineering. This has fueled a series of significant scientific advances over the past 4 years, bringing Escape only months away from the creation of the world's first universal pluripotent stem cell source. Escape's primary areas of focus include type I diabetes, acute myocardial infarction, and acute and chronic skin wounds.
Escape's mission is to transform healthcare through innovating cures rather than band-aid medicines. Escape will be the first company worldwide to enable cell-based therapeutics to achieve a universal, off-the-shelf status.